|
|
|
Stem Cell Related Patent Number US6849448
| Title: | Pigs and pig cells having an inactivated α 1,3-galactosyl transferase gene | | Inventors: | D'Apice, Anthony J. F.; Balwyn, Australia | | Summary: | This invention describes a new alpha-1,3-galactosyltransferase and leukaemia inhibitor factor, its corresponding DNA and nucleic acid constructs for inactivating the transferase gene. The invention relates to human pre-formed xenoantibodies which play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed herein are materials and methods for removing or neutralizing such antibodies, as well as materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are described as forming as the result of activity by the enzyme alpha-1,3 galactosyltransferase. Also included is the porcine gene encoding alpha-1,3 galactosyltransferase and methods of inactivating the gene in mammalian cells and embryos. Nucleic acid constructs are provided which are useful for inactivating the alpha-1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture. Also discussed are therapeutic applications such as in the elimination of hyperacute regions in human transplants. | | Abstract: | Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed are materials and methods for removing or neutralizing such antibodies. Also disclosed are materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are formed as the result of activity by the enzyme α-1,3 galactosyltransferase. The porcine gene encoding α-1,3 galactosyltransferase is disclosed, as are materials and methods for inactivating (“knocking out”) the α-1,3 galactosyltransferase gene in mammalian cells and embryos. Included are nucleic acid constructs useful for inactivating the α-1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6849448 | | Application Number: | US1997000984900 | | Date Filed: | 04/12/1997 | | Date Published: | 01/02/2005 | | Assignee: | BresaGen Limited Australia |
|
|
